Pediatric Interventional Radiology & Oncology Course: Oncology Review for Pediatric IRs

Sunday, November 3, 2024, 8:00 AM - Monday, November 4, 2024, 5:00 PM, St. Jude Children's Research Hospital, Memphis, TN

Interested in Pediatric Interventional Oncology?

Want a better understanding of the rationale behind current pediatric oncology care?

St. Jude Children’s Research Hospital and the Pediatric Biomedical Imaging Initiative are proud to host the PBII Pediatric Interventional Radiology & Oncology Course: Oncology Review for Pediatric IRs to be held November 3-4, 2024, in Memphis, TN.

The course will review:

Cancer Biology, Clinical Trials, And Standard Therapies
Epidemiology And Biology of Pediatric Cancers
Approaches To Clinical Trials Including Oncologic and Radiologic Endpoints
Standard Therapies Used to Treat Pediatric Cancers
Common Pediatric Tumors and Current Treatment Approaches
Cancer Biology and Current Treatment Approaches to Hematologic, Solid, And Central Nervous System Tumors
Providing Care at End of Life
Interventional Oncology Techniques and Potential Roles in Children
Vascular Interventions: Radioembolization, Chemoembolization and Novel Approaches
Non-Vascular Interventions: Ablation, Pain Interventions
Current Status of Adult and Pediatric Interventional Oncology
The Future: How Do We Establish Pediatric Interventional Oncology Techniques in Pediatric Oncology Care?
Strategy Discussions:
Working With Colleagues and Established Cancer Collaborative Research Groups
Creation Of International Pediatric Interventional Radiology Research Collaborative
Brainstorming Research and Registry Ideas

1. Explain cancer epidemiology, cause and various treatment approaches.
2. Discuss oncology clinical trial design and endpoints (in particular, tumor metrics classification systems)
3. Identify common pediatric tumors as well as successes and issues in current treatment approaches.
4. Describe current pediatric interventional oncology techniques approaches and status of literature.

Please note that we are offering this course in person only.

Registration close October 24th at 11:59pm. 

Registrant                                             Fee

General Attendees                                      $500

St. Jude/ LeBonheur employees  $150

 LMIC/trainees     $150

St. Jude Children's Research Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

St. Jude Children’s Research Hospital designates this Live Activity for a maximum of 13.00 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ (13.00 hours), Non-Physician Attendance (13.00 hours)

We are pleased to offer group rates at the following Marriott Bonvoy property in Downtown Memphis:

Courtyard Memphis Downtown $169 USD per night

Book your room before September 30, 2024 to ensure group rate and hotel availability. St. Jude will provide shuttle service between the Courtyard Hotel and the St. Jude campus.

Arriving via all other ground transportation including private car or car for hire requires prearranged security access for each attendee and may cause delays.

Other recommended Downtown Memphis hotels: Moxy Downtown, SpringHill Suites, The Peabody, Hotel Napoleon, Hu. Hotel, and The Westin. Please note, a hotel group rate is not offered and transportation to St. Jude is not provided from these hotels.

For more information about Memphis, visit memphis.stjude.org

The faculty for this activity are listed below. Click to view the faculty member's financial disclosure information and bio. 

Mitigation of Relevant Financial Relationships

St Jude Children's Research Hospital adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (ie, companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.